A CAR T cell therapy for children and young adults with medulloblastoma that came back
Original title: GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new cell therapy for a brain tumor that came back or did not go away.
Who this trial is for. This trial is for children and young adults whose medulloblastoma came back or did not go away. It tests CAR T cells made to target a protein called GPC2. Some people with other brain tumors of the same early cell type may also take part.
Where it stands. The trial has not reported results. It is checking whether these cells can be made for each person. It is also checking how safe the treatment is. The answers are not in yet.
What this means, and what it doesn't
What it could mean: This is an early test of a new kind of treatment. It is done at one site. A family whose child fits the study may want to ask their care team about it. The care team can explain what it would involve.
What it doesn't mean: This does not mean the therapy works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.